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Therapeutic potential of the 
phosphino Cu(I) complex 
(HydroCuP) in the treatment of 
solid tumors
Valentina Gandin1, Cecilia Ceresa2, Giovanni Esposito3, Stefano Indraccolo3, Marina Porchia  4, 
Francesco Tisato4, Carlo Santini  5, Maura Pellei5 & Cristina Marzano1
[Cu(thp)4][PF6] (HydroCuP) is a phosphino copper(I) complex highly soluble and stable in physiological 
media that has been developed as a possible viable alternative to platinum-based drugs for anticancer 
therapy. HydroCuP potently inhibited the growth of human cancer cells derived from solid tumors 
by inducing endoplasmatic reticulum (ER) stress thus leading to cell death through paraptosis with a 
preferential efficacy against cancer rather than non-cancer cells. Aim of the present study was to assess 
the therapeutic potential of HydroCuP in vivo, in syngenic and xenograft murine models of solid tumors 
by triggering the Unfolded Protein Response (UPR) pathway. With respect to platinum drugs, HydroCuP 
induced a markedly higher reduction of tumor growth associated with minimal animal toxicity. In 
human colorectal cancer xenografts, chemotherapy with HydroCuP was extremely effective in both 
oxaliplatin-sensitive and resistant models. The favorable in vivo tolerability of HydroCuP was also 
correlated to an encouraging biodistribution profile. Additionally, no signs of drug-related neurotoxicity 
and nephrotoxicity were observed. Altogether, these results demonstrate that HydroCuP appears 
worth of further investigation to evaluate its therapeutic activity towards a broad spectrum of solid 
malignancies.
Although highly effective toward a number of solid tumors1 platinum anticancer drugs (cisplatin, CDDP, and 
the second and third generation analogues carboplatin and oxaliplatin, OXP)2 cause severe toxic effects on 
normal tissues and induce early appearance of resistance phenomena, even at the beginning of their adminis-
tration or after the first therapeutic cycles1,3,4. These drawbacks have stimulated an extensive search to develop 
alternative strategies based on different metallodrugs with improved pharmacological properties and aimed at 
different targets5,6. Many coordination compounds that can attack cancer interfering with biological processes 
other than DNA replication have been proposed7. Examples of alternative molecular targets for metal-based 
drugs include thiol-containing proteins, proteasome, matrix metalloproteases, telomerases, topoisomerases, 
glutathione-S-transferases, and histone deacetylases8.
DNA damaging agents, like platinum drugs, promote DNA lesions that stall DNA replication and collapse rep-
lication forks, resulting in cell death. However, if not repaired properly, many of these genomic insults can induce 
gene mutations or chromosomal alterations. It is noteworthy that some patients treated with cisplatin develop 
cancer due to cisplatin-induced DNA lesions approximately 10 years after therapy8. Thus, developing anticancer 
agents that kill rapidly dividing cells with minimal potentially deadly side effects of chromosomal alterations and 
mutagenesis would be highly desirable.
In this field, copper complexes showed encouraging perspectives9–13. Copper-based complexes have been 
investigated on the assumption that endogenous metals may be less toxic for normal cells with respect to cancer 
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cells. The altered metabolism of cancer cells and differential response between normal and tumor cells to copper 
are the basis for the development of copper complexes endowed with antineoplastic characteristics.
Recent findings have confirmed that copper complexes represent good alternatives to platinum drugs14. 
Actually, copper species, besides possessing a broader spectrum of activity and a lower toxicity, are able to over-
come inherited and/or acquired resistance to cisplatin. These features are consistent with the hypothesis that 
copper complexes possess mechanism(s) of action different from those shown by platinum drugs. So far, little 
information is available on the molecular basis for the mode of action of copper complexes. At present, most 
investigations still focus on the potential ability of these complexes or fragments thereof, to interact with DNA. 
However, other cellular constituents such as topoisomerases or the proteasome multiprotein complex are emerg-
ing as new putative targets14–17.
Since Cu(I) is the chemical form generally accepted by the bioinorganic community to describe the active 
internalization of physiological copper in mammalian cells through copper transporter (CTR) proteins, examples 
of Cu(I) complexes displaying antitumor potential are being developed day by day14.
However, for very few of them the in vivo activity has been evaluated. This is likely related to the intrinsic dif-
ficulty to stabilize copper(I) species, especially in aqueous media. Thus tuning the hydrolysis and the activation of 
the redox machinery to minimize off-target binding in blood while maintaining enough reactivity to inhibit the 
cellular target, should be a guiding principle in the design of novel anticancer copper(I) complexes.
Hydrophilic tertiary phosphanes (P) have been used to obtain stable, water-soluble [Cu(P)4]+-type species 
that proved to be easy to handle during in vitro tests and showed promising antiproliferative effects18,19. Among 
them, the monocationic [Cu(thp)4][PF6] complex (HydroCuP) (thp = tris-hydroxymethylphosphine) showed 
an excellent in vitro antitumor activity against a wide range of solid tumors, including platinum drug refrac-
tory/resistant tumors20. Moreover, HydroCuP was much less cytotoxic against non-tumor cells than Pt(II) drugs 
with selectivity index (SI, the quotient of the average IC50 toward non-malignant cells divided by the average 
IC50 for the malignant cells) values about 35- and 10-fold higher than those calculated for CDDP and OXP, 
respectively21. Electrospray ionization mass spectrometry (ESI-MS) studies revealed that the original [Cu(P)4]+ 
pro-drugs underwent dissociation with production of coordinative unsaturated [Cu(P)3]+ and [Cu(P)2]+ spe-
cies, which represented key intermediates for the activation of potential biological properties22. Furthermore, by 
means of a mechanistic detailed study we proposed the involvement of human copper transporter 1, hCtr1, in 
the mechanisms for HydroCuP cellular entry23. Although expression of hCtr1 is ubiquitous because all the tissues 
require copper, studies showed that expression levels were highly variable among normal tissues and also human 
malignancies14.
By molecular and cellular studies, HydroCuP was found to inhibit chymotrypsin-like (CT-L), trypsin-like 
(T-L) and caspase-like (C-L) catalytic activities of 26S proteasome causing intracellular accumulation of polyubiq-
uitinated proteins and functional suppression of the ubiquitin-proteasome pathway, thus triggering endoplasmic 
reticulum (ER) stress and the concomitant induction of unfolded protein response (UPR). The irreversible ER 
stress was accompanied with a massive cytoplasmatic vacuolization and triggering of a type of a programmed cell 
death (PCD) alternative to apoptosis and termed paraptosis21. The ability to activate paraptosis makes HydroCuP 
a very promising agent to tackle apoptosis resistance in cancer cells. It is worth mentioning that HydroCuP 
was found particularly effective against a series of human cultured colon cancer cells21. Colorectal cancer is at 
the top of the list of the most common cancers worldwide, with around 1 million new cases diagnosed every 
year24. Early-stage colorectal cancer is frequently curable with surgery, but the appearance of metastases often 
leads to fatal consequences for the patient25. Oxaliplatin is a third generation platinum compound and the first 
platinum-based compound to show efficacy in the treatment of colorectal cancer26 and approved for therapy as a 
front-line agent27. It is a key drug in FOLFOX (folinic acid, 5-fluorouracil, and OXP) regimen for the treatment 
of colorectal cancer. Similarly to CDDP, the efficacy of OXP is limited by the development of cellular resistance. 
Moreover, it causes severe and disabling sensory peripheral neurotoxicity due to accumulation of the drug in the 
dorsal root ganglia (DRG), where sensory neurons are located28,29. Presently, there are no other drugs in advanced 
clinical development for the treatment of patients with oxaliplatin-refractory colorectal cancer.
Based on these premises, in this study we performed a pre-clinical investigation on the therapeutic potential of 
HydroCuP in 3D colon cancer cell cultures and in three independent murine models, including the highly aggres-
sive Lewis Lung Carcinoma (LLC) as an example of syngeneic murine model and two mouse xenograft models, 
the LoVo colorectal oxaliplatin-sensitive xenograft and the LoVo colorectal oxaliplatin-resistant xenograft.
The novel phosphino copper(I) complex, HydroCuP, suppressed tumor growth in both the syngeneic and 
xenograft models, being also able to overcome OXP-resistance without causing evident toxic or side effects. To 
our knowledge, this is the first copper(I) complex reported to inhibit cell growth of oxaliplatin-resistant cancer 
cells in an in vivo tumor model.
Results and Discussion
In vitro antitumor activity on 3D colon cancer cell cultures. The effect of HydroCuP on different pan-
els of 2D human cancer cell cultures had been already evaluated19–21, showing that HydroCuP yielded IC50 values 
ranging from less than 0.3 µM to 3 µM being up to 50- and 30-fold more cytotoxic than CDDP and OXP, respec-
tively. Notably, HydroCuP showed a significant antiproliferative activity against cancer cells derived from solid 
tumours, including mainly colon carcinoma cells. However, it has been recently well described that in two-dimen-
sional (2D) monolayer cell cultures cellular activities are often altered and their typical in vivo functions resulted 
to be lost. As a result, the conventional 2D cell culture provides limited predictive capacity for drug testing.
As attractive alternative, 3D cell cultures have proven to be a physiologic mimic of the in vivo tissue because 
they produce a similar cellular microenvironment30. Actually, on a three-dimensional architectural organization, 
tumor cells are not uniformly exposed to nutrients or oxygen in vitro, thus closely mimicking the organization 
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of human tumors. Furthermore, significant differences were described in terms of sensitivity to drugs among 2D 
and 3D cultures due to significant differences in terms of growth, migration, morphology and gene expression30.
In order to improve the predictive capacity of the in vitro assays, we tested HydroCuP activity in two 3D cell 
cultures of human colon cancer cells, HCT-15 and LoVo. The colon cancer spheroids were treated with HydroCuP 
for 72 h and the cell viability was assessed by means of the acid phosphatase (APH) assay (Fig. 1, panel A). For 
comparison purposes, the cytotoxicities of CDDP and OXP were evaluated in the same experimental conditions.
In both colon cancer spheroid models, HydroCuP yielded IC50 values very similar to those of OXP and about 
2.5 lower than those obtained with CDDP. In addition, monitoring the morphology of the spheroids (see Fig. 1, 
panel B), whereas untreated spheroids showed a compact and cohesive morphology (a), HydroCuP-treatment 
induced a time-dependent disaggregation of spheroids, determining a substantial decrease in the spheroid com-
pactness (b and c).
In vivo antitumor activity towards Lewis Lung Carcinoma (LLC). The in vivo antitumor activity of 
HydroCuP was firstly tested in the highly aggressive, poorly immunogenic mouse LLC implanted intramuscularly 
(i.m.) in C57BL mice. The tumour growth inhibition induced by treatment with copper(I) complex was evaluated 
both in LLC model and compared with that promoted by the reference metallo-drug, CDDP.
The schedule of HydroCuP administration in vivo was initially determined by assessing the total dose that 
could be injected without undue toxicity for different schedules in nontumor-bearing C57BL mice (data not 
shown). HydroCuP has been administered in aqueous solution taking advantage of its excellent water solubil-
ity (>2.0 mg/mL at pH 7.4) and good solution stability, enabling in vivo formulation using 0.9% NaCl normal 
saline21,22. Three schedules of i.p. HydroCuP were administered: early treatment (days 3, 5, 7 and 9 after tumor 
inoculum), intermediate treatment (days 7–14) and late treatment with split-doses (days 9–11 with a loading 
dose and days 12–14 with a lower maintenance dose). Table 1 shows the results obtained in LLC-bearing mice fol-
lowing the different treatment schedules. After 24 h from tumor implantation, mice were randomly divided into 
five groups (8 animals per group, 10 controls). Cisplatin treatment schedule was selected according to standard 
protocols designed to optimize its efficacy and minimize the occurrence of adverse events31. For the early treat-
ment, control mice received the vehicle (0.9% NaCl). HydroCuP was dosed at 25, 35 and 50 mg/kg i.p. on days 3, 
5, 7, 9, 11 and 13 after tumor implantation. Cisplatin was dosed at 1.5 mg/kg i.p. on days 3, 5, 7, 9, 11 and 13 after 
tumor implantation. At day 15, control and treated animals were sacrificed, and the inhibition of tumor growth 
was evaluated.
As shown in Table 1, HydroCuP treatment resulted in a dose-dependent inhibition of proliferation of tumor 
cell population. HydroCuP exerted a statistically significant antitumor activity compared to vehicle-treated mice 
(P < 0.05), even at the lower daily dose of 25 mg/kg with a tumor growth inhibition of 26%. Mice treated with 
50 mg/kg of HydroCuP showed a tumor growth inhibition slightly higher to that observed for mice treated with 
1.5 mg/kg of cisplatin. Over the course of 15 days, changes in the body weight of tumor-bearing mice were daily 
monitored (Fig. 2, panel A). Chemotherapy with HydroCuP did not induce significant body weight loss and no 
signs of discomfort were evident, whereas mice treated with cisplatin appeared prostrate and showed substantial 
weight loss.
The most rigorous preclinical evaluation of an antineoplastic agent is to determine its ability to induce 
responses in well-established tumors. To test the therapeutic efficacy of HydroCuP in animals with advanced dis-
ease, LLC tumors were allowed to establish and grow to visible and palpable size before the start of chemotherapy. 
Figure 1. Activity in 3D cell cultures. (A) Spheroids (2.5 × 103 cells/well) were treated for 72 h with increasing 
concentrations of tested compounds. The growth inhibitory effect was evaluated by means of APH test. IC50 
values were calculated from the dose-survival curves by four parameter logistic model (P < 0.05). SD = standard 
deviation. (B) Representative images (10x) of HCT-15 3D culture: a = controls; b = spheroids treated with IC50 
concentrations of HydroCuP for 24 h; c = spheroids treated with IC50 concentrations of HydroCuP for 48 h.
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In the intermediate treatment schedules, from day seven after tumor inoculation (visible tumor) LLC-bearing 
mice were daily treated i.p. with HydroCuP at 30 and 50 mg/kg whereas CDDP was dosed daily at 1.5 mg/kg 
i.p. At day 15, control and treated animals were sacrificed, and the inhibition of tumor growth was evaluated. 
Noteworthy, administration of HydroCuP at 50 and 30 mg/kg induced 85% and 82% reduction of the tumor 
mass, respectively, compared to that of the control group (Table 1). A similar effect was exerted by CDDP (87% 
reduction), however, the time course of body weight changes indicated that CDDP induced elevated weight loss, 
while treatment with HydroCuP resulted in a body weight loss <10% (Fig. 2, panel B).
In the late treatment schedule with split-doses, 9 days after tumor inoculation (palpable tumor) treated ani-
mals received a higher loading dose of 50 mg/kg followed by a low maintenance dose of 30 mg/kg of HydroCuP. 
At this dosing regimen, the administration of HydroCuP resulted in a quite complete tumor regression (about 
95%) already after the sixth administration. The results summarized in Table 1 clearly show that a complete dis-
appearance of primary tumors in mice was confirmed by dissection on day 15. CDDP dosed at 1.5 mg/kg induced 
a tumor regression of 73%. The time course of body weight changes depicted in Fig. 2, panel C, indicates that 
treatment with HydroCuP did not induce any adverse effects including significant body weight loss throughout 
the therapeutic experiment.
Tissue distribution in LLC-bearing mice. To better understand the pharmacology and toxicology of the 
novel copper(I) complex, tissue samples, collected from LCC-bearing C57BL mice were analysed. Figure 3 shows 
tissue distribution of HydroCuP in LLC-bearing mice. On day 10 after tumor implantation, mice were treated 
with a single i.p. injection of 50 mg/kg of HydroCuP. After 24 hours, animals were sacrificed and copper content 
was quantified by graphite furnace atomic absorption spectroscopy (GF-AAS) analysis in several organs and 
normalized to control mice tissues. The solid tumor mass presented the highest copper concentration (at least 
1.4 times higher than that detected in spleen), followed by spleen, kidney, liver and stomach. These results clearly 
indicate a great bioavailability to the malignant tissue of parenteral administration of HydroCuP. Interestingly, 
with respect to control animals, no enhance in copper content was detectable in brain, thus suggesting that 
HydroCuP was not able to cross the blood–brain barrier.
In vivo antitumor activity toward human colorectal cancer xenografts. We have previously shown 
that HydroCuP markedly inhibited cell viability of human colon cancer cells corresponding to different stages of 
disease progression and mostly characterized by the predominance of antiapoptotic factors or defects in apoptosis 
effectors21. HydroCuP was also able to overcome OXP resistance in human colon cancer cells21. On this basis, we 
investigated whether these properties translated into tumor growth inhibition in preclinical in vivo models of 
human colorectal cancers. To this aim, we developed the OXP-sensitive and OXP-resistant LoVo xenografts in 
BALB/c nu/nu mice. OXP-resistant Lovo cells were obtained following 22 months of selection and were about 
Compound Dose (mg·kg−1)
Average tumor weight 




controla — 0.638 ± 0.01 —
HydroCuP 25 0.473 ± 0.12* 25.86
HydroCuP 35 0.273 ± 0.04** 57.21
HydroCuP 50 0.113 ± 0.04** 82.28
CDDP 1.5 0.168 ± 0.10** 73.66
Intermediate treatment
controla — 0.502 ± 0.16 —
HydroCuP 30 0.088 ± 0.03** 82.37
HydroCuP 50 0.071 ± 0.02** 85.85
CDDP 1.5 0.061 ± 0.03** 87.84
Late treatment
controla — 0.432 ± 0.21 —
HydroCuP 50 (days 9–11) 30 (days 12–14) 0.024 ± 0.03** 94.44
CDDP 1.5 0.118 ± 0.10** 72.68
Table 1. Treatment of LLC. avehicle (0.9% NaCl). Lewis lung carcinoma (LLC) was implanted i.m. into the right 
hind leg of 8-week old imbred C57BL mice. After 24 h from tumor implantation, mice were randomly divided 
into groups of 8 animals (10 controls). Early treatment: HydroCuP was dosed at 25, 35 and 50 mg/kg i.p. on days 
3, 5, 7, 9, 11 and 13 after tumor implantation. CDDP was dosed at 1.5 mg/kg i.p. on days 3, 5, 7, 9, 11 and 13 after 
tumor implantation. Intermediate treatment: Chemotherapy was delayed until the tumor became visible (day 
7). Day 7–14: animal received 30 and 50 mg/kg of HydroCuP or 1.5 cisplatin mg/kg daily i.p. Late treatment: 
Chemotherapy was delayed until the tumor became palpable (day 9). From day 9 to day 11, HydroCuP was 
dosed daily at 50 mk/kg i.p. whereas from day 12 to day 14 at 30 mg/kg i.p. CDDP was dosed daily at 1.5 mg/
kg i.p. At day 15 animals were sacrificed, legs amputated at the proximal end of the femur, and the inhibition of 
tumor growth was determined as the difference in weight of the tumor-bearing leg and the healthy leg expressed 
as percentage referred to the control animals. *p < 0.05, **p < 0.01.
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17-fold resistant to OXP18. OXP-sensitive or OXP-resistant LoVo cells (1 × 107) were injected in the flank of mice. 
Once tumor was established (tumor volumes of about 0.4 cm3, around 14 days after tumor inoculation), mice 
were randomly divided into six groups (6 animals per group, 8 controls). The HydroCuP-treated groups (6 mice 
each group) received daily 30 mg/kg by i.p. injection and the OXP-treated group was given 2 mg/kg by i.p. injec-
tion. At day 30, animals were sacrificed, and the inhibition of tumor growth was determined (Fig. 4, panel A). 
Measurements of body weights were recorded from day 14 every 2 days until the experimental endpoint (Fig. 4, 
panel B).
Compared with tumor growth in control mice receiving vehicle (0.9% NaCl), OXP markedly delayed tumor 
growth (about 55%) only in LoVo model whereas in LoVo-resistant model the tumor growth inhibition reached 
only 20%. Conversely, HydroCuP demonstrated a statistically significant decrease in final tumor volume (about 
65%) compared with the control, both in LoVo and in LoVo-resistant models (Fig. 4, panel A). No significant 
difference in body weight and appearance of deterioration in health was observed between the HydroCuP treated 
and the control group thus indicating a minimal animal toxicity (Fig. 4, panel B). In contrast, in both LoVo and 
LoVo-resistant xenografts, treatment with OXP induced a body weight loss of about 23%. Overall, these data 
confirming the HydroCuP ability to overcome OXP resistance also in vivo are very promising preclinical data that 
could suggest a new therapeutic approach against this subset of colon cancer.
Neurotoxicity studies. As widely described in the literature, peripheral neuropathy is the most common 
dose-limiting toxicity of CDDP and OXP, and it is one of the major causes of discontinuation of therapy25,26. In 
Figure 2. Body weight changes. The body weight changes of LLC bearing-C57BL mice treated with vehicle or 
tested compounds following early (A), intermediate (B) and late (C) treatments. Weights were measured every 
two days. Error bars indicate the S.D. **P < 0.01; *P < 0.05.
www.nature.com/scientificreports/
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particular, OXP is reported by the Food and Drug Administration to be responsible for more than 70% rate of 
symptomatic neurotoxicity with any severity27, and often leads to treatment suspension32,33.
To investigate the potential neurotoxic effect of HydroCuP, we employed a well-established in vitro model 
based on organotypic cultures of DRG from 15-day-old rat embryos. Neurite elongation under NGF influence 
was evaluated in DRG explants. DRG are the neuronal structures most severely affected in platinum-induced 
peripheral neurotoxicity and DRG explants model is particularly useful since it permits to make prediction of 
potential neurotoxic effects of the tested drug in a clinical setting. This model has been widely used to study the 
neurotoxic effect of several anticancer drugs showing reliable results34–37. For comparison purposes, the effect 
induced by the reference drugs OXP and CDDP was also tested. As expected, after 48 h CDDP and OXP treat-
ment significantly reduced neurite elongation in a dose-dependent manner (Fig. 5, panel A). In particular, OXP at 
7.5 µM reduced by 50% neurite length (Fig. 5, panel B). On the contrary, HydroCuP showed no neurotoxic effect 
even at the highest concentrations (Fig. 5, panel C). These findings propose HydroCuP as a much safer agent, in 
terms of neurotoxicity, compared with platinum drugs.
Nephrotoxicity studies. As stated before, for platinum compounds the irreversible and acute kidney 
damage is one of the main problems that occurs during clinical applications. Despite of preventive precautions, 
indeed, irreversible renal damage occurs in about one-third of patients under cisplatin treatment34.
The potential nephrotoxic effect of HydroCuP was evaluated by measuring some specific biomarkers in 
urines obtained from 8-week-old male Sprague Dawley rats treated with a single i.p. injection of HydroCuP and 
CDDP. Urines of the treated animals were collected after 24, 72 and 120 h, and urinary total protein (uTP) and 
N-acetyl-β-D-glucosaminidase (NAG) were evaluated as signs of nephrotoxicity. As expected, CDDP induced a 
significant increase of uTP excretion (Fig. 5, panel D) and NAG (Fig. 5, panel E). On the contrary, treatment with 
HydroCuP determined a 24 h excretion of uTP roughly 12 times lower than that recorded with CDDP (Fig. 5, 
panel D). Following 120 h, the levels of uTP excreted by HydroCuP were 11 times lower compared with the ref-
erence metallodrug.
On the other hand, NAG activity detected after injection with HydroCuP was up to 12 times lower compared 
to those detected after injection of CDDP (Fig. 5, panel E). These results clearly suggest for HydroCuP a scarce 
nephrotoxic potential compared to that showed by the clinically approved metallodrug, CDDP.
Histopathological Examination. We previously demonstrated that HydroCuP is able to induce parap-
tosis in human LoVo colon cancer cells by triggering ER stress leading to the UPR21. In particular, treatment 
with HydroCuP in vitro was found to provoke a time-dependent increase in the phosphorylation of both protein 
kinase R-like endoplasmic reticulum kinase (PERK) and inositol requiring enzyme (IRE-1), two of the major 
transducers of endoplasmic reticulum (ER) stress21.
In the initial phases of UPR induction, the activated cytosolic domain of PERK phosphorylates the eIF2alpha, 
inhibiting nuclear translation and resulting in cell death. In addition, the activated cytosolic domain of IRE1 acts 
on its substrate XBP1 which translocating into the nucleus activating UPR-target genes21.
In order to investigate the in vivo activation of the UPR induced by HydroCuP, the levels of the phospho-PERK 
(p-PERK) and phospho-IRE1 (p-IRE1) were detected in tumor samples derived from treated LCC-bearing mice 
(following later-stage regimen). Figure 6 shows microphotographs of control and HydroCuP-treated tumor sam-
ples by IHC analysis. In control samples, p-PERK staining was found moderate in cytoplasm (in about 40% cell 
population) and intense in perinuclear-ER (about 5% of cell population). IHC of tumor exposed to HydroCuP 
treatment revealed no difference in cytoplasmic p-PERK positivity whereas perinuclear-ER p-PERK staining 
significantly increase (about 30%) in comparison to controls. With regard to the downstream p-PERK effector, 
Figure 3. Tissue distribution in LLC bearing C57BL mice. C57BL mice were inoculated i.m. on the right flank 
with LLC cells (2 × 106). After 10 days, HydroCuP was administered i.p. at a dose of 50 mg/kg. The mice were 
sacrificed after 24 hours and tumor, brain, spleen, kidney, intestine, liver and stomach were excised. Tissues were 
washed in ice-cold saline and weighed after removing excess fluid. All samples were mineralized in HNO3 and 
Cu content in each sample was measured by GF-AAS. Error bars indicate the S.D. **P < 0.01; *P < 0.05 (tumor 
vs organs).
www.nature.com/scientificreports/
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p-IRE1, control tumors were weakly positive in cytoplasm (in about 15% cell population). HydroCuP-treated 
tumor samples showed a marked increase in cytoplasmic positivity (about 35% cell population) in p-IRE1 IHC. 
Overall, the intense perinuclear-ER p-PERK immunoreactivity and the substantial increase of cytoplasmatic 
p-IRE1 observed in tumor sections suggest the involvement of this effectors in the cell death mechanism induced 
by HydroCuP.
These IHC data are consistent with our previous in vitro observations, and confirm that HydroCuP acts in vivo 
by inducing the UPR pathway.
Conclusions
The systematic studies of medicinal chemistry aimed at identifying new metallodrugs led us to select HydroCuP, a 
phosphino copper(I) complex highly soluble and stable in physiological media. HydroCuP has exquisite potency 
against human cancer cells derived from solid tumors, being preferably effective towards malignant rather than 
non-malignant cells. In agreement with our previous in vitro data, here we confirmed by using 3D-cultures that 
HydroCuP strongly inhibited cell growth of human colon cancer cells. More importantly, HydroCuP inhibited 
tumor growth in preclinical models much strongly with respect to both platinum reference drugs. Tested against 
the highly aggressive, poorly immunogenic murine LLC, HydroCuP caused a quite complete tumor regression, 
and towards human colorectal cancer xenografts, chemotherapy with HydroCuP was highly effective in both 
OXP-sensitive and -resistant models, thus attesting HydroCuP ability to overcome OXP-resistance. To the best of 
our knowledge, this is the first example of a copper(I) complex reported to inhibit cell growth of OXP-resistant 
cancer cells in an in vivo tumor model. The histopathological results, confirming that HydroCuP acted by 
Figure 4. In vivo activity toward LoVo and LoVo-OXP tumor xenografts. (A) LoVo and LoVo-OXP tumor 
xenografts in 6-week-old BALB/c nu/nu mice by injecting 1 × 107 tumor cells subcutaneously on the left dorsal 
flank. After 24 h from tumor implantation, mice randomly divided into six groups (6 animals per group). 
Chemotherapy delayed until day 14 (tumor volumes of about 0.4 cm3). From day 14, HydroCuP dosed daily at 
30 mg/kg i.p., OXP dosed daily at 2 mg/kg i.p. At day 30, animals sacrificed, and the inhibition of tumor growth 
determined by comparing the volume of the control group and the treatment group expressed as percentage 
referred to the control animals. Error bars indicate the S.D. *p < 0.05, **p < 0.01, with respect to control. (B) 
The body weight changes of LLC-bearing C57BL mice treated with vehicle or tested compounds. Body weight 
was measured every two days and was taken as a parameter of systemic toxicity. The error bars indicate the S.D. 
**P < 0.01; *P < 0.05.
www.nature.com/scientificreports/
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inducing the UPR pathway, were in line with those already obtained in cultured LoVo cells. In addition, contrary 
to platinum drugs, treatment with HydroCuP did not induce severe adverse effects including significant body 
weight loss. The favorable in vivo tolerability of HydroCuP was correlated to an encouraging biodistribution 
profile demonstrating that it accumulated preferentially in the tumor mass. Experiments on DRG organotypic 
cultures treated with HydroCuP did not show evidence of peripheral neurotoxicity whereas the monitoring 
of urinary biomarkers for nephrotoxicity did not track renal injury in HydroCuP treated mice. Even though 
further organ toxicity assessments are needed, these latter preclinical data are very promising, as neurotoxicity 
and nephrotoxicity are the most severe dose-limiting side effects associated with platinum drug chemotherapy. 
Altogether, our results demonstrate that HydroCuP appears worth of further investigation to evaluate its thera-
peutic activity towards a broad spectrum of solid malignancies.
Figure 5. Neurotoxicity studies. OXP and HydroCuP toxicity at 48 h in DRG explants from 15 day-embryonic 
Sprague-Dawley rats. Representative images of neurite length in maturing DRG explants with different 
concentrations of OXP and HydroCuP (A). Bar: 500 µm. Percentage reduction curve of DRG treated with OXP 
(B) and HydroCuP (C) with respect to the controls (mean ± S.D., P < 0.05). Nephrotoxicity studies. Eight-
week-old male Sprague Dawley rats were treated with a single i.p. injection of HydroCuP, CDDP or the vehicle 
solution (saline solution, control). Rats were then placed into metabolic cages and urines collected after 24, 72 
and 120 h. Afterwards urines were centrifuged and aliquoted to measure creatinine, uTP (D) and NAG (E). 
Error bars indicate the S.D.
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Methods
Experiments with human cells. HydroCuP, CDDP and OXP (Sigma Chemical Co.) were dissolved in 
0.9% NaCl solution just before the experiment.
Cell line and spheroid culturing. Human colon (HCT-15 and LoVo) carcinoma cell lines were obtained by 
American Type Culture Collection (ATCC, RocKville, MD). Cells were routinely cultured in RPMI-1640 medium 
(Sigma Chemical Co.) containing 10% foetal heat-inactivated calf serum (FCS; Euroclone, Milan, Italy), antibiot-
ics (50 units/mL penicillin and 50 mg/mL streptomycin) and 2 mM L-glutamine. All cultures were kept at 37 °C in 
Figure 6. IHC analysis of p-PERK and p-IRE1 expression in LLC tumor samples. (A) Pictures show 
representative patterns of p-PERK and p-IRE1 expression by IHC in control LLC tumor samples (a and c) and 
in HydroCuP-treated tumor samples (b and d); magnification: ×10. (B) p-PERK (a) and p-IRE1 (b) values, 
evaluated in LLC tumor sections. The quantification of IHC images was performed by using Image J software. 
Columns indicate quantitative analysis in n = 3 different tumors per group; *P < 0.05.
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a humidified atmosphere with 5% CO2. Cell transfer and preparation of single-cell suspensions were performed 
by mild enzymatic dissociation using a 0.05% trypsin and 0.02% EDTA solution in PBS (Euroclone, Milan, Italy).
Spheroids were initiated in liquid overlay by seeding 2.5 × 103 HCT-15 and LoVo cells/well in phenol red-free 
RPMI-1640 medium (Sigma Chemical Co.), containing 10% FCS and supplemented with 20% methyl cellulose 
stock solution. A total of 150 μl of this cell suspension was transferred to each well of a round bottom non-tissue 
culture treated 96 well-plate (Greiner Bio-one, Kremsmünster, Austria) to allow spheroid formation within 72 h.
Cell viability assays. A modified APH assay, which is based on quantification of cytosolic acid phosphatase 
activity, was used for determining cell viability in spheroids38. Briefly, the pre-seeded spheroids were treated 
with fresh medium containing the compound to be studied at the appropriate concentration (range 5–150 μM). 
Triplicate cultures were established for each treatment. After 72 h, each well was treated with 100 μL of the assay 
buffer (0.1 M sodium acetate, 0.1% Triton-X-100, supplemented with ImmunoPure p-nitrophenyl phosphate; 
Sigma Chemical Co.) and, following 3 h of incubation, 10 μL of 1 M NaOH solution were added. The inhibition 
of the cell growth induced by the tested complexes was detected by measuring the absorbance of each well at 
405 nm, using a Bio-Rad 680 microplate reader. Mean absorbance for each drug dose was expressed as a per-
centage of the control untreated well absorbance (T/C) and plotted vs drug concentration. IC50 values, the drug 
concentrations that reduce the mean absorbance at 405 nm 50% of those in the untreated control wells, were cal-
culated by four-parameter logistic (4-PL) model. Evaluation was based on means from at least four independent 
experiments.
In vivo experiments. All experiments were performed according to D.L.vo 26/2014, which regulates the use 
of experimental animals in Italy. The research project was approved by the Italian Health Department according 
to the art. 20 of above mentioned D.L.vo.
In vivo anticancer activity toward LLC. The mice were purchased from Charles River, Italy, housed in steel cages 
under controlled environmental conditions (constant temperature, humidity, and 12 h dark/light cycle), and ali-
mented with commercial standard feed and tap water ad libitum. The LLC cell line was purchased from ECACC, 
United Kingdom. The LLC cell line was maintained in DMEM (Euroclone, Pero, Italy) supplemented with 10% 
heat-inactivated foetal bovine serum (Euroclone, Pero, Italy), 10 mM L-glutamine, 100 U/mL penicillin, and 
100 µg/mL streptomycin in a 5% CO2 air incubator at 37 °C. The LLC was implanted intramuscularly (i.m.) as a 
2 × 106 cell inoculum into the right hind leg of 8-week old male and female C57BL mice (24 ± 3 g body weight). 
The antitumor activity of HydroCuP in LLC tumor model has been investigated by means of different schedules 
(early treatment, intermediate treatment and late treatment) and compared with that promoted by the reference 
metallodrug, CDDP. In the early-stage treatment, animals were treated at day 3, 5, 7, 9, 11 and 13 after the tumor 
cell inoculum with an i.p. injection of HydroCuP (25, 35 and 50 mg/kg), CDDP (1.5 mg/kg) or the vehicle solution 
(0.9% NaCl).
In the intermediate treatment, animals were treated after 7 days from tumor implantation (visible tumor) 
with daily i.p. doses of HydroCuP (30 and 50 mg/kg), CDDP (1.5 mg/kg) or the vehicle solution (0.9% NaCl). In 
the late treatment, animals were treated after 9 days from tumor implantation (palpable tumor) with i.p. doses 
of HydroCuP (50 mg/kg) from day 9 to day 11 and with i.p. doses of HydroCuP (30 mg/kg) from day 12 to day 
14, or with daily doses of CDDP (1.5 mg/kg) or with the vehicle solution (0.9% NaCl). At day 15, animals were 
sacrificed, the legs were amputated at the proximal end of the femur, and the inhibition of tumor growth was 
determined according to the difference in weight of the tumor-bearing leg and the healthy leg of the animals 
expressed as a percentage referring to the control animals. Body weight was measured every 2 days and was taken 
as a parameter for systemic toxicity.
Biodistribution studies in LLC-bearing mice. C57BL mice were inoculated i.p. on the right flank with LLC cells 
(2 × 106). After 10 days from tumor implantation, HydroCuP was administered i.p. at a dose of 50 mg/kg. The 
mice were sacrificed after 24 h and tumor, brain, spleen, kidney, intestine, liver and stomach were excised. Tissues 
were washed in ice-cold saline and weighed after removing excess fluid. All samples were mineralized in HNO3 
and Cu content in each sample was measured by GF-AAS (Graphite Furnace Atomic Absorption Spectroscopy).
In vivo anticancer activity toward colorectal oxaliplatin-sensitive and –resistant xenograft models. LoVo and 
LoVo-OXP tumor xenografts were established in 6-week-old BALB/c nu/nu mice by injecting 1 × 107 tumor cells 
subcutaneously (100 μL in serum free medium) on the left dorsal flank. After 24 h from tumor implantation, mice 
were randomly divided into six groups (6 animals per group, 8 controls). Chemotherapy was delayed until the 
tumor was about 0.4 cm3 (day 14). From day 14, HydroCuP was dosed daily at 30 mg/kg i.p. whereas OXP was 
dosed daily at 2 mg/kg i.p. Measurements of body weights and tumor volumes were recorded from day 14 every 2 
days until the experimental endpoint. The long axis (L) and the short axis (S) were measured with callipers, and 
the tumor volume (V) was calculated using the following equation: V = SxSxL/2. At day 30, animals were sacri-
ficed, and the inhibition of tumor growth was determined by comparing the volume of the control group and the 
treatment group expressed as percentage referred to the control animals.
Nephrotoxicity studies. Eight-week-old male Sprague Dawley rats were randomly allocated to five groups (five 
animals per group) and treated with a single i.p. injection of HydroCuP (50 mg/kg) or the vehicle solution (0.2 mL 
saline solution, control). Cisplatin (1.5 mg/kg,) was also used under the same experimental conditions for com-
parison purposes. Rats were then placed into metabolic cages and urines collected after 24, 72 and 120 h. Later, 
urines were centrifuged (150 g for 10 minutes at room temperature) to discard debris and aliquoted to meas-
ure creatinine, uTP and NAG. Urine creatinine assays were performed using creatinine assay kit from Sigma 
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Chemical Co. (St. Louis, MO). uTPs were measured by means of BioRad Total Protein Test (Hercules, CA). 
Urinary NAG was measured spectrophotometrically with the NAG kit (Roche diagnostics, Basel, Switzerland) 
according to the manufacturer’s protocols. uTP and NAG are expressed as grams per millimoles of creatinine 
(g mmol−1 creatinine).
DRG Explants and Assessment of Neurite Outgrowth from DRG. DRG from E15 Sprague-Dawley rats (Envigo, 
San Pietro al Natisone, Italy) were aseptically removed and cultured onto a single layer of rat tail collagen surfaces 
in 35-mm dishes as previously described36.
The DRG were incubated in AN2 medium [MEM added with 1.4 mM L-glutamine (Euroclone, Pero, 
Italy), 10% calf bovine serum (Hyclone, Thermo Scientific, Logan, UT) 50 µg/ml ascorbic acid, 0.6% glucose 
(Sigma-Aldrich) in the presence of 5 ng/ml nerve growth factor (NGF; Life Technologies, Monza, Italy) in a 5% 
CO2 humidified incubator at 37 °C.
To evaluate the neurotoxicity of HydroCuP and OXP, the DRG explants were treated for 2 h with NGF and 
subsequently exposed to each drug at different concentrations for 48 h. OXP was tested at 5, 7.5 and 10 μM while 
5, 10 and 20 μM of HydroCuP was used. DRG treated with AN2 medium supplemented with 5 ng/ml NGF alone 
were used as controls. Phase-contrast micrographs were taken, and the length of the longest neurite in each DRG 
was measured by Image J (NIH, Bethesda, MD), using a standard calibration grating photographed at the same 
magnification. A compound is considered neurotoxic when the mean neurite elongation is reduced by 50% or 
more after drug exposure vs control.
Immunohistochemical Analysis. To evaluate p-PERK and p-IRE1 expression, five-micron-thick 
formalin-fixed, paraffin-embedded (FFPE) tumor samples of LLC models (3 tumors/group, 3 sections/tumor 
and 3 images/sections) were stained by IHC using anti-human p-PERK (Thr981, Santa Cruz) or p-IRE1 
(Ser724, Abcam) primary antibodies according to the manufacturer’s instructions. IHC was performed using a 
Leica Bond III Autostainer (Leica). Antigen retrieval was performed in citrate buffer for 15 min. Sections were 
counter-stained with Mayer’s haematoxylin. IHC results were evaluated by one experienced pathologist with 
no prior knowledge of experimental data. The quantification of IHC images was performed by using Image J 
software.
Statistical analysis. All values are the means ± SD of no less than three measurements starting from three 
different cell cultures. Multiple comparisons were made by ANOVA followed by the Tukey−Kramer multiple 
comparison test (**P < 0.01; *P < 0.05), using GraphPad Software.
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